Combining a TLR9 agonist (CpG) with a polyspecific integrin‐binding peptide (PIP) to generate a tumor‐targeting immunomodulator, referred to as PIP‐CpG, triggered tumor regression and prolonged the survival of mice with BC tumors. This evidence concerns the gene TLR9 and breast cancer.